IV for­mu­la­tion of Scynex­is' lead an­ti­fun­gal gets side­lined by the FDA as reg­u­la­tors probe blood clots

Shares of the mi­cro­cap biotech Scynex­is $SCYX were blood­ied this evening af­ter the FDA or­dered in­ves­ti­ga­tors to slam the brakes on any stud­ies of an IV for­mu­la­tion of its lead drug af­ter three healthy vol­un­teers ex­pe­ri­enced blood clots.

The FDA or­dered the halt so reg­u­la­tors could com­plete a re­view of all avail­able pre-clin­i­cal and clin­i­cal da­ta of the IV for­mu­la­tion of SCY-078, an an­ti-fun­gal. And its shares quick­ly plunged 30% on the news. The mi­cro­cap had a mar­ket cap of $78 mil­lion at the close, ahead of the sharp drop.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER